FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130307711> ?p ?o ?g. }

• W2130307711 endingPage "1195" @default.
• W2130307711 startingPage "1189" @default.
• W2130307711 abstract "Objective To investigate whether treatment initiated with an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) for patients with ischemic heart disease, hypertension, or diabetes causes a reduction in hemoglobin (Hb) levels. Patients and Methods This was a retrospective cohort analysis using the computerized database of a large health maintenance organization. Included were all adults with a first purchase of an ACE-I, an ARB, or a calcium channel blocker (CCB) between January 1, 2004, and December 31, 2009, defined as the index date. Measures of Hb levels before and 1 year after the index date were reviewed, and the change was calculated. All the analyses were stratified by pharmaceutical class. The main exposure variables were the proportion of days covered (PDC) by these drugs and the mean enalapril dosage (for enalapril users only). Results Levels of Hb before and after treatment were available for 14,754 patients taking ACE-Is, 751 taking ARBs, and 3087 taking CCBs. A high PDC was significantly associated with greater yearly reductions in Hb levels compared with a low PDC for CCB use, but was more pronounced for ACE-I and ARB use. A high PDC was also associated with a higher odds of developing anemia in ACE-I users (odds ratio [OR], 1.59; P<.001) and ARB users (OR, 2.21; P=.05). In nonanemic enalapril users, every 10-mg increment in daily dose was associated with an OR of 1.45 for the development of anemia (P<.001). The association remained after excluding nonadherent patients. Conclusion Levels of Hb are reduced during the first year of use of ACE-Is and to a lesser extent with use of ARBs. This association is dose dependent and is not explained by patient adherence." @default.
• W2130307711 created "2016-06-24" @default.
• W2130307711 creator A5006065398 @default.
• W2130307711 creator A5011630968 @default.
• W2130307711 creator A5030578698 @default.
• W2130307711 creator A5043401432 @default.
• W2130307711 creator A5061280877 @default.
• W2130307711 creator A5061426528 @default.
• W2130307711 creator A5075691382 @default.
• W2130307711 creator A5085418141 @default.
• W2130307711 date "2012-12-01" @default.
• W2130307711 modified "2023-09-27" @default.
• W2130307711 title "Association of Angiotensin-Converting Enzyme Inhibitor Therapy Initiation With a Reduction in Hemoglobin Levels in Patients Without Renal Failure" @default.
• W2130307711 cites W1980582359 @default.
• W2130307711 cites W1985372653 @default.
• W2130307711 cites W1995085584 @default.
• W2130307711 cites W2036541320 @default.
• W2130307711 cites W2051833563 @default.
• W2130307711 cites W2065103594 @default.
• W2130307711 cites W2079131964 @default.
• W2130307711 cites W2084576011 @default.
• W2130307711 cites W2100727588 @default.
• W2130307711 cites W2107195787 @default.
• W2130307711 cites W2116757005 @default.
• W2130307711 cites W2130238504 @default.
• W2130307711 cites W2134832377 @default.
• W2130307711 cites W2135393879 @default.
• W2130307711 cites W2147610358 @default.
• W2130307711 cites W2156520140 @default.
• W2130307711 cites W2914847286 @default.
• W2130307711 doi "https://doi.org/10.1016/j.mayocp.2012.07.020" @default.
• W2130307711 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3547548" @default.
• W2130307711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23141116" @default.
• W2130307711 hasPublicationYear "2012" @default.
• W2130307711 type Work @default.
• W2130307711 sameAs 2130307711 @default.
• W2130307711 citedByCount "18" @default.
• W2130307711 countsByYear W21303077112013 @default.
• W2130307711 countsByYear W21303077112014 @default.
• W2130307711 countsByYear W21303077112015 @default.
• W2130307711 countsByYear W21303077112017 @default.
• W2130307711 countsByYear W21303077112018 @default.
• W2130307711 countsByYear W21303077112019 @default.
• W2130307711 countsByYear W21303077112021 @default.
• W2130307711 countsByYear W21303077112022 @default.
• W2130307711 countsByYear W21303077112023 @default.
• W2130307711 crossrefType "journal-article" @default.
• W2130307711 hasAuthorship W2130307711A5006065398 @default.
• W2130307711 hasAuthorship W2130307711A5011630968 @default.
• W2130307711 hasAuthorship W2130307711A5030578698 @default.
• W2130307711 hasAuthorship W2130307711A5043401432 @default.
• W2130307711 hasAuthorship W2130307711A5061280877 @default.
• W2130307711 hasAuthorship W2130307711A5061426528 @default.
• W2130307711 hasAuthorship W2130307711A5075691382 @default.
• W2130307711 hasAuthorship W2130307711A5085418141 @default.
• W2130307711 hasBestOaLocation W21303077112 @default.
• W2130307711 hasConcept C126322002 @default.
• W2130307711 hasConcept C134018914 @default.
• W2130307711 hasConcept C156957248 @default.
• W2130307711 hasConcept C164705383 @default.
• W2130307711 hasConcept C167135981 @default.
• W2130307711 hasConcept C27016395 @default.
• W2130307711 hasConcept C2775940317 @default.
• W2130307711 hasConcept C2778248108 @default.
• W2130307711 hasConcept C2778917026 @default.
• W2130307711 hasConcept C2779611605 @default.
• W2130307711 hasConcept C555293320 @default.
• W2130307711 hasConcept C71924100 @default.
• W2130307711 hasConcept C72563966 @default.
• W2130307711 hasConcept C84393581 @default.
• W2130307711 hasConceptScore W2130307711C126322002 @default.
• W2130307711 hasConceptScore W2130307711C134018914 @default.
• W2130307711 hasConceptScore W2130307711C156957248 @default.
• W2130307711 hasConceptScore W2130307711C164705383 @default.
• W2130307711 hasConceptScore W2130307711C167135981 @default.
• W2130307711 hasConceptScore W2130307711C27016395 @default.
• W2130307711 hasConceptScore W2130307711C2775940317 @default.
• W2130307711 hasConceptScore W2130307711C2778248108 @default.
• W2130307711 hasConceptScore W2130307711C2778917026 @default.
• W2130307711 hasConceptScore W2130307711C2779611605 @default.
• W2130307711 hasConceptScore W2130307711C555293320 @default.
• W2130307711 hasConceptScore W2130307711C71924100 @default.
• W2130307711 hasConceptScore W2130307711C72563966 @default.
• W2130307711 hasConceptScore W2130307711C84393581 @default.
• W2130307711 hasIssue "12" @default.
• W2130307711 hasLocation W21303077111 @default.
• W2130307711 hasLocation W21303077112 @default.
• W2130307711 hasLocation W21303077113 @default.
• W2130307711 hasLocation W21303077114 @default.
• W2130307711 hasOpenAccess W2130307711 @default.
• W2130307711 hasPrimaryLocation W21303077111 @default.
• W2130307711 hasRelatedWork W1966732677 @default.
• W2130307711 hasRelatedWork W1980328605 @default.
• W2130307711 hasRelatedWork W2009148223 @default.
• W2130307711 hasRelatedWork W2070577472 @default.
• W2130307711 hasRelatedWork W2076601757 @default.
• W2130307711 hasRelatedWork W2411578912 @default.
• W2130307711 hasRelatedWork W2415502382 @default.

• next